Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.

Paragraph: Such hedge funds, often cast as villains of the piece because they bet against share prices, scent a profit from company valuations they believe are unduly inflated by ESG promises or which they say ignore risks that threaten to undermine the company’s prospects. The fact short-sellers, who look to exploit information gaps, are targeting the ESG sphere underlines the complexities facing investors in accurately gauging companies’ sustainability credentials. Teenage climate activist Greta Thunberg last week spoke of CEOs masking inaction with “creative PR”. Against a backdrop of growing public and political concerns about climate change and economic inequality, companies are under increasing pressure to show they are taking greater responsibility for how they generate their profits. Investments defined as “sustainable” account for more than a quarter of all assets under management globally, according to the Global Sustainable Investment Alliance. About $31 trillion has been invested, buoyed by analyst reports that show companies with strong ESG narratives outperform their peers. Some short-sellers, including Carson Block of Muddy Waters, Josh Strauss of Appleseed Capital and Chad Slater of Morphic Asset Management, argue share prices can be bolstered by corporate misrepresentation about sustainability, or so-called “greenwashing”. “Greenwashing is absolutely rampant now,” says Slater, whose fund bets on both rising and falling share prices. If companies fail to engage with long-term investors, he sees a red flag. “From the short side, it’s quite interesting.”  Analytics companies that provide corporate ESG ratings use a combination of company disclosures, news sources and qualitative analysis of third-party data. They are a major source of information for investors, but it is not an exact science. Hedge funds have various strategies for selecting targets, often focusing on those they think show both ESG and more traditional financial or operational weakness. A high ESG rating can attract short interest. A Reuters analysis of data from financial information company Refinitiv and national regulators in Britain, France, Germany, Spain and Italy shows the five companies in each country with the best ESG scores collectively were being shorted more than those with the worst scores. The short positions against the companies deemed to have the best ESG credentials were 50% greater in size than those placed against the worst-performers. (Graphic: ESG shorts - UK:  here)  For an interactive version of the graphic, click here tmsnrt.rs/2RwpBDj. For additional graphics covering the other countries mentioned, see related content. ESG data providers compile ratings based on a slew of  measures ranging from energy usage to board gender make-up, salary gap data and the scale of negative press reports on the company from newspapers across the world. Refinitiv, part-owned by the parent company of Reuters News, factors in more than 400 ESG measures for each company, taken from a range of sources including company reports, regulatory filings, NGO websites and news articles. A key problem, though, is scant regulations governing what ESG measures and risks companies must disclose and their patchy nature, said Diederik Timmer, executive vice president of client relations at Sustainalytics, a major ESG data provider. “When things go well, companies report quite well on those, when things don’t go so well it gets awfully quiet,” he added. Some policymakers, largely in Europe, are pushing for standardized disclosures to help investors better gauge the risks, something which will leave less wriggle room for companies and make scores even more reliable. Two leading global asset managers interviewed by Reuters,  who manage nearly $1 trillion in assets but declined to be identified, said they had tested their portfolios using several data providers and found the correlation between ESG ratings to be so low, they are building their own ranking system. Peter Hafez, chief data scientist at RavenPack, which helps hedge funds analyze data to get a trading edge, agreed. “There’s no perfect ESG rating out there,” he said. The influence of news flows on investor sentiment was underlined by a Deutsche Bank study here published in September that mapped 1,600 stocks and millions of company announcements and climate-related media reports over two decades. It found companies that had a greater proportion of positive announcements and press over the preceding 12 months outperformed the MSCI World Index by 1.4% a year, on average, while those with more negative news underperformed by 0.3%. For graphics of the data, click here tmsnrt.rs/2ncsFY0 and here tmsnrt.rs/2nd5hcT. Short-sellers borrow shares, pay the lender a fee and sell them on, betting the price will fall before buying them back and returning them to the original lender - pocketing the difference, minus the fee. But it is not for the faint-hearted. If funds trigger a share price fall, they can earn millions, but the downside, should shares rise, is unlimited. The perils of the practice were shown by the shorts burnt by a 17% surge in the shares of Elon Musk’s Tesla (TSLA.O) in October after a surprise quarterly profit. Short-sellers suffered paper losses of $1.4 billion, erasing most of their 2019 profits, according to analytics firm S3 Partners. And in a decade-long stock market bull-run, short-selling can be tricky. Morphic’s joint chief investment officer Slater said the Sydney-based money manager’s standalone short positions in its Trium Morphic ESG long-short fund had weighed on the portfolio over the past 12 months. Niche activist short-sellers, who can torpedo company valuations by publishing negative reports on targets - often alleging fraud or serious failures - are often criticized for undermining long-term company objectives and blurring the lines between whistleblower and market manipulator. Short-sellers agree they are biased, but argue no more than long investors, the banks that raise money for the company and the company’s management. Carson Block, founder of American short-seller Muddy Waters, who shot to prominence spotting wrongdoing in some Chinese-run companies, is now seeking a “morality short” on ESG - branching out from a traditional focus on corporate governance issues to targets whose success he says hinges on secretly harming society. As an example of what he is seeking, he points to the U.S. opioid crisis, which has triggered around 2,500 lawsuits by authorities seeking to hold drugmakers responsible for stoking a scandal that has claimed almost 400,000 overdose deaths between 1999 and 2017. “I’m really skeptical of ESG,” he says, likening the use of the acronym by the corporate world to the token straw slipped into a large plastic cup with a plastic lid. “ESG is the paper straw of investing,” he says. “I definitely want to find companies like that because I know they’re out there and I want to help put them down.” Claim: Villains or visionaries? Hedge funds short companies they say 'greenwash'.
2

Paragraph: Italy has concluded Covid-19 is not a virus, and people are actually dying of amplified global 5G electromagnetic radiation poisoning. Italy disobeyed world health law from the WHO saying not to carry out autopsies on Covid-19 patients. The WHO never said autopsies couldn’t take place. Italy has found that Covid-19 is actually disseminated intravascular coagulation (thrombosis). The way to cure this is antibiotics, anti-inflammatories and anticoagulants. Antibiotics do not directly treat Covid-19, which is caused by a virus. The anti-inflammatory ibuprofen is being trialled for use against Covid-19 and an anticoagulant has been used in some Covid-19 cases. Aspirin is not a specific cure. Covid-19 is not a virus, but a bacterium being amplified by 5G which causes inflammation and hypoxia. Covid-19 patients can get secondary infections from bacteria. Hypoxia and types of inflammation can be symptoms of Covid-19. There’s no proof Covid-19 is in any way related to 5G. People with Covid-19 should take aspirin 100mg and Apronax or paracetamol. Trials into both of these drugs’ effectiveness in treating Covid-19 are ongoing, but haven’t concluded yet. Paracetamol can ease symptoms but isn’t a specific treatment. Covid-19 clots the blood causing thrombosis, stopping blood flow and oxygenating the heart and lungs. Severe Covid-19 can cause blood clotting problems and issues like this have been seen in Covid-19 patients, but this is not the only thing that can be fatal in patients. In a day, Italy sent home more than 14,000 patients after treating them with Aspirin and Apronax. The Italian Medicines Agency doesn’t mention aspirin or apronax in its list drugs used to treat Covid-19 outside of clinical trials. And there’s no record of a day when 14,000 people were sent home from hospital in Italy. There is an order to incinerate or immediately bury Covid-19 bodies without autopsy. There is no such order. Claim 1 of 10 Claim: Covid-19 clots the blood causing thrombosis, stopping blood flow and oxygenating the heart and lungs.
0

Paragraph: An image that purports to show a screengrab from a medical journal was featured on a tweet that gained traction on January 15 2020.The tweet contains a capture of this citation:It says:Hormone replacement therapy has many nicknames among transfeminine people, including titty pills, titty skittles, smartitties, chicklets, anticistamines, mammary mints, life savers, tit tacs, breast mints, femme&m’s, antiboyotics, trans-mission fluid, and the Notorious H.R.T.“oh fuck this was in an actual medical journal I’m gonna cry lmao,” the user wrote.While it is legitimate, many of the users sharing it may not be aware of the context behind it. The citation was included in an article published by the McGill Journal of Law and Health, a publication covering healthcare-related law. The story itself is a first-person account by activist Florence Ashley regarding their experience seeking medical care both pre-and post-gender transition.Their listing of the nicknames for hormone replacement therapy (HRT) appears alongside a passage covering the temporary effects from stopping the treatment prior to reassignment surgery:I had to stop taking the hormones three weeks before surgery, give or take a few days. I was ill-prepared for this endeavour. Because hormones regulate emotions, amongst many other things, changes in hormonal regimen can have a heavy impact on mood stability and mental health. In my case, the fluctuations were large enough that I had to raise my dosage of antidepressant.A few months after surgery, my reflection in the mirror elicited an emotional reaction I had not yet grown accustomed to. After over a year on hormone replacement therapy, my body had changed in ways that finally began feeling comfortable. After decades of discontent, I was finally feeling at home in what I had previously described as a flesh prison. It had only taken a few weeks without hormones to lose what I estimated as six months of progress, noticeable in terms of fat redistribution, breast tissue loss, and changes to sexual functioning. The mirror served me a cruel reminder of this loss of self.In their paper, Ashley argues that current regulations covering disclosure of information between medical providers and transgender patients rely “on overly narrow conceptions of informed consent and underestimates the role that communal knowledge should play in health care.”Their own surgeon, for example, did not mention what the side effects would be of stopping HRT prior to surgery.“I would not have changed my mind about having surgery, it is true, but I could have done more to prepare had I known about the impact of ceasing hormone replacement therapy,” they wrote:Knowing in advance is crucial to psychological preparation and adaptation. Armed with knowledge, I could have scheduled appointments with my therapist, warned my loved ones about my increased need for support and softness, and refrained from in-person commitments. I did the latter two of those for a subsequent surgical procedure. Claim: "An article published in a medical journal makes reference to nicknames for hormone replacement therapy that included ""antiboyotics, trans-mission fluid, and the Notorious H.R.T."

2

